Online citations, reference lists, and bibliographies.
← Back to Search

Evaluation Of Novel Lipid Based Formulation Of β-Artemether And Lumefantrine In Murine Malaria Model.

Sushant C. Patil, S. Suryavanshi, S. Pathak, S. Sharma, V. Patravale
Published 2013 · Biology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
The present investigation aims at formulating lipid based drug delivery system of β-Artemether and Lumefantrine and comparative pharmacological evaluation with innovator formulation. Commercial modified oil and indigenous natural fatty acids comprised the oily phase in developing lipidic formulation of β-Artemether and Lumefantrine. The developed system was characterized for mean globule size, stability by freeze thaw cycles, and birefringence. Developed formulation and innovator formulation were compared for their in vivo anti-malarial activity at different dose levels in male Swiss mice, infected with lethal ANKA strain of Plasmodium berghei. The percent parasitemia, activity against time and animal survival period were examined. On fourth day of antimalarial studies, at normal and ½ dose levels, formulations revealed zero percent parasitemia while control showed 33.92±6.00% parasitemia. At 1/10 dose level, developed and innovator formulations revealed zero percent parasitemia upto 11th day, however, three mice from innovator formulation demonstrated recrudescence after 12th day. Both the formulations at normal dose and ½ dose levels showed 100% activity and survival whereas at 1/10 dose level, innovator formulation showed, 62.5% survival. The developed lipidic system of β-Artemether and Lumefantrine exhibited excellent antimalarial activity with 100% survival.
This paper references
10.1016/J.PLIPRES.2007.10.002
New advances in fatty acids as antimalarial, antimycobacterial and antifungal agents.
N. Carballeira (2008)
10.1086/338257
Prevention of malaria in children.
P. Fischer (2002)
10.1016/J.ADDR.2007.05.006
Oral lipid-based formulations.
D. Hauss (2007)
10.1038/nrd1416
Antimalarial drug discovery: efficacy models for compound screening
D. Fidock (2004)
10.1080/00034983.1975.11686997
The chemotherapy of rodent malaria, XXII. The value of drug-resistant strains of P. berghei in screening for blood schizontocidal activity.
W. Peters (1975)
10.1016/j.ijpharm.2008.06.012
Solid microemulsion preconcentrate (NanOsorb) of artemether for effective treatment of malaria.
M. Joshi (2008)
EVALUATING FLOW PROPERTIES OF SOLIDS
R. L. Carr (1965)
10.1007/BF02976689
Commonly used surfactant, Tween 80, improves absorption of P-glycoprotein substrate, digoxin, in rats
H. Zhang (2003)
10.1208/s12249-008-9131-z
Development and Evaluation of Lorazepam Microemulsions for Parenteral Delivery
A. Kale (2008)
10.2165/00003088-199937020-00002
Clinical Pharmacokinetics and Pharmacodynamics of Artemether-Lumefantrine
N. White (1999)
10.1016/J.ADDR.2007.10.010
Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies.
C. Pouton (2008)
A clinical and pharmacokinetic trial of six doses of Artemether–Lumefantrine for multidrug-resistant Plasmodium falciparum
G. Lefèvre (2001)
10.1016/J.EJPB.2004.03.001
Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system.
Marc Lindenberg (2004)
10.1016/S1471-4922(01)02031-1
The past, present and future of childhood malaria mortality in Africa.
R. Snow (2001)
10.1023/A:1011984216775
Dissolution Testing as a Prognostic Tool for Oral Drug Absorption: Immediate Release Dosage Forms
J. Dressman (2004)
10.1172/JCI115678
Antimalarial properties of n-3 and n-6 polyunsaturated fatty acids: in vitro effects on Plasmodium falciparum and in vivo effects on P. berghei.
L. Kumaratilake (1992)
10.1046/J.1365-2125.1997.00573.X
Single dose pharmacokinetics of oral artemether in healthy Malaysian volunteers.
M. N. Mordi (1997)
10.2165/00044011-199918060-00006
Clinical Pharmacokinetics of Artemether and Lumefantrine (Riamet®)
G. Lefèvre (1999)
World Health Organization . Guidelines for the treatment of Malaria ( WHO / HTM / MAL / 2006 . 1108 )
P. Olumese (2006)
10.1201/9781420028300-16
Powder Flow Properties
K. Johanson (2005)
World Health Organization. Guidelines for the treatment of Malaria (WHO/HTM/MAL/2006.1108), http://www.who.int/ malaria/docs/TreatmentGuidelines2006.pdf
P. Olumese (2006)
10.1006/EXPR.1995.1097
Antimalarial effects of C18 fatty acids on Plasmodium falciparum in culture and on Plasmodium vinckei petteri and Plasmodium yoelii nigeriensis in vivo.
M. Krugliak (1995)
10.1046/J.1365-2125.1998.00830.X
Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients.
F. Ezzet (1998)
10.1016/J.ADDR.2007.10.012
Biopharmaceutical challenges associated with drugs with low aqueous solubility--the potential impact of lipid-based formulations.
C. O'Driscoll (2008)
Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine.
N. White (1999)
10.4269/AJTMH.2001.64.247
A clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug-resistant Plasmodium falciparum malaria in Thailand.
G. Lefèvre (2001)
10.1023/A:1016268311867
Lipid Microemulsions for Improving Drug Dissolution and Oral Absorption: Physical and Biopharmaceutical Aspects
P. Constantinides (2004)
10.1002/JPS.2600671011
Enhancement of bioavailability of a hydrophobic amine antimalarial by formulation with oleic acid in a soft gelatin capsule.
Vittorio Stella (1978)
10.4103/0975-7406.84463
Formulation and characterization of lipid-based drug delivery system of raloxifene-microemulsion and self-microemulsifying drug delivery system
H. Thakkar (2011)
10.1007/BF00257745
Effects of polysorbate 80 on the absorption and distribution of oral methotrexate (MTX) in mice
M. N. Azmin (2004)



This paper is referenced by
10.9734/jpri/2020/v32i1330589
Preparation and Physicochemical Evaluation of Lumefantrine-2-Hydroxypropyl-β-cyclodextrin Binary Systems
A. Adegbola (2020)
10.4155/tde-2016-0092
Antimalarial solid self-emulsifying system for oral use: in vitro investigation.
Sameer Bhandari (2017)
10.22271/phyto.2018.v7.isp6.1.17
Development and validation of HPLC-UV method for quantification of artemether in plasma
Vaishali Yogesh Jadhav (2018)
10.1111/jphp.12795
Improved pharmacokinetic and pharmacodynamic attributes of artemether–lumefantrine‐loaded solid SMEDDS for oral administration
Sameer Bhandari (2017)
Development and evaluation of a self-emulsifying drug delivery system for artemether and lumefantrine
Lauren Cilliers (2017)
10.1016/j.ijpharm.2016.09.008
Nanostructured lipid carriers of artemether-lumefantrine combination for intravenous therapy of cerebral malaria.
P. Prabhu (2016)
10.1016/j.ijpharm.2016.07.021
Artemether-lumefantrine nanostructured lipid carriers for oral malaria therapy: Enhanced efficacy at reduced dose and dosing frequency.
P. Prabhu (2016)
S0031182020002036jra 122..128
Dawei Wang (2021)
SOLUBILITY AND BIO-AVAILABILITY ENHANCEMENT OF ANTIMALARIAL DRUGS: ARTEMETHER AND LUMEFANTRINE THROUGH SOLID LIPID NANO PARTICLES
Sanjana Gaikwad (2018)
10.1007/s13346-020-00770-z
Nanobiotechnological modules as molecular target tracker for the treatment and prevention of malaria: options and opportunity
Jain Anamika (2020)
10.3109/10717544.2014.905883
Development of artemether and lumefantrine co-loaded nanostructured lipid carriers: physicochemical characterization and in vivo antimalarial activity
D. Parashar (2016)
10.1017/S0031182020002036
Determination of lumefantrine as an effective drug against Toxoplasma gondii infection – in vitro and in vivo study
Dawei Wang (2020)
10.36468/pharmaceutical-sciences.648
Enhancing Solubility and Bioavailability of Artemether and Lumefantrine through a Self-nano Emulsifying Drug Delivery System
S. N. Gaikwad (2020)
10.1016/j.ijpharm.2016.10.064
In-situ single pass intestinal permeability and pharmacokinetic study of developed Lumefantrine loaded solid lipid nanoparticles.
A. Garg (2017)
Semantic Scholar Logo Some data provided by SemanticScholar